You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline

You are reading 1 of 2 free-access articles allowed for 30 days

Cortisol the focus of 2019 IES McKenna lecture

By Mindo - 22nd Oct 2019 | 15 views

Prof Mark Sherlock delivered this year’s McKenna Lecture at the 2019 IES Annual Meeting, which took place in the Ardilaun Hotel, Co Galway, from 11-12 October.

His lecture was titled ‘The Ups and Downs of Cortisol: From Endocrinology to Intracrinology’.

Speaking to the Medical Independent (MI), Prof Sherlock, Consultant Endocrinologist, Beaumont Hospital, Dublin, said that his research work was focused on studies that he carried out in Birmingham, UK, and then later studies in Ireland.

The lecture concerned “mortality due to glucocorticoid excess, tissue-specific regulation of glucocorticoid action, the role of cortisol in obesity and insulin resistance, and the effects of hydrocortisone replacement therapy on metabolism, and also on quality-of-life and cardiovascular risk,” he said.

In the lecture, Prof Sherlock asked “could the hydrocortisone treatment we are giving our patients be leading to adverse effects?”

“It certainly could,” he told MI.

“It depends on dose; it depends on a number of different issues, but I think it’s something we need to be aware of in our clinical practice.”

He referred to a research presentation made during the meeting by Dr Rosemary Dineen, titled ‘Modified-Release Hydrocortisone Improves Cardiovascular Risk Profile in Patients with Primary and Secondary Adrenal Insufficiency’.

“She found when she put a large cohort of patients on this medication, this new Plenadren modified-release hydrocortisone, that the blood pressure was lower, their weight went down. Again, the question you would always worry about in patients with adrenal insufficiency is, could they have been hypo-adrenal? But actually, their quality-of-life improved in nearly every questionnaire,” he said.

“One-hundred per cent of them decided at the end of the study if they had the option — not that they do, because it’s not reimbursed at the moment — they would stay on the modified-release hydrocortisone because they felt better in general… a lot of these studies have really been about trying to balance between the morbidity and mortality we see in patients on hydrocortisone and with cortisol excess, and I think with studies looking at large patient populations trying to phenotype these patients very clearly, we may be getting towards a balance between under- and over-placement,” he concluded.

Speaking about the state of the specialty in general, Prof Sherlock said: “I think endocrinology in Ireland is really strong at the moment. I think we have a fantastic group of consultants, of researchers, of trainees coming through, so I think it’s in a really healthy state — we’ve been really lucky over the last couple of years to be able to get people who have been in overseas centres to come back to our hospitals and back to our research institutes to work, so it’s in a really healthy, optimistic state.”

He also feels positive about the future of endocrinology, both within and outside Ireland.

“There’s a European Rare Disease Network for Endocrinology. That is a call from the European Union; we’re hoping that Ireland will get in on that call… that’s happening in the next year, hopefully. I think just [it is important] to continue all the good work that the society for endocrinology does with its members, particularly trainees coming through, and trying to get more and more people involved in research… that and looking after patients — you can really improve the healthcare system by combining the two of those.”

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read